The Globe and Mail reports in its Friday, April 5, edition that Raymond James analyst Rahul Sarugaser commenced coverage on Oncolytics Biotech with an "outperformer" recommendation and $3 share target. The Globe's David Leeder writes that analysts on average target the shares at $7.58. Mr. Sarugaser says in a note: "Oncolytics's most advanced clinical assets include Phase 2 programs in breast and pancreatic cancer; both programs have received FDA fast track designation. In this Moonshots-themed report, we focus on Oncolytics's opportunity in pancreatic cancer, given the dire unmet need for efficacious treatments, alongside pelareorep's impressive tripling of objective response rates (GOBLET trial) and doubling of 12-month overall survival rates vs. benchmark data. We see the potential for Oncolytics to submit NDAs for pelareorep in both pancreatic and metastatic breast cancer in 2027/8, yielding a large potential market opportunity. In the interim, we anticipate a succession of value-creating catalysts, including multiple looks at clinical data, and, with a collection of well-heeled Pharmas already hanging around the hoop, we assign a non-zero probability to Oncolytics securing material partnerships."